ArticleFrontiers in immunology2025
Metabolic profiles in laryngeal cancer defined two distinct molecular subtypes with divergent prognoses.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolism and Metabolic Reprogramming in Laryngeal Squamous Cell Carcinoma.Biomedicines · 2026Review
- Resistance-oriented immunometabolic circuits in laryngeal squamous cell carcinoma: glycolysis-lactate signaling, mitochondrial stress, and tumor-myeloid crosstalk.Frontiers in immunology · 2026Review
- Non-coding RNAs in laryngeal squamous cell carcinoma: diagnostic biomarkers and emerging exosome-based therapeutic strategies.Cancer cell international · 2025Review
- NSD Family-Mediated H3K36 Methylation in Human Cancer: Mechanisms and Therapeutic Opportunities.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal cancer (LCA) is the second most common type of head and neck malignancy, characterized by high recurrence rates and poor overall survival (OS). However, progress in curing LCA through molecular-targeted diagnostics and therapies is slow and limited. The occurrence and progression of cancer are closely associated with metabolic reprogramming. Therefore, this study aimed to identify metabolism-related LCA subtypes through a comprehensive analysis of transcriptomic, mutational, methylation, and single-cell RNA sequencing, in hopes of finding factors which influences the prognosis of LCA. Methods: First, to identify metabolism-related LCA subtypes, data from 114 patients with LCA from The Cancer Genome Atlas (TCGA) dataset were collected for an unsupervised clustering analysis, which focused on the expression characteristics of survival-related metabolic genes. Subsequently, prognostic and diagnostic models have been developed using machine learning techniques. Specifically, the prognostic model utilized the least absolute shrinkage and selection operator (LASSO) Cox regression, whereas the diagnostic model was built using the Random Forest (RF) algorithm. Furthermore, to ensure the reproducibility, the results of the subtypes and models were validated using three independent bulk RNA datasets and a scRNA-seq dataset. Results: Two robust subtypes were identified and independently validated. Each subtype has a distinct prognostic outcomes and molecular features. Specifically, the Conclusion: This study offers new perspectives for patient stratification and presents opportunities for therapeutic development in LCA. Furthermore, we explored the potentials of several key tumor markers for both diagnosis and prognosis prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.